Cardiac structure and function in renal disease

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 1, 1996, Pages 102-106

  Amann, Kerstin ^a   Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAUSE OF DEATH; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FIBROSIS; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; MYOCARDIAL DISEASE; PRIORITY JOURNAL; REVIEW; UREMIA;

ENDOMYOCARDIAL FIBROSIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; RISK FACTORS; UREMIA;

EID: 0029968070     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199601000-00017     Document Type: Review

References (62)

1. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994, 8: 1136-1142.
2. Gris JC, Branger B, Vecina F, Al Sabadani B, Fourcadi J, Schred JF: Increased cardiovascular in dialyzed uraemic patients. Kidney Int 1994, 46:807-813.
3. Ansari A, Kaupke CJ, Vaziri ND, Miller R, Barbari A: Cardiac pathology in patients with end-stage renal disease maintained on haemodialysis. Int J Artif Organs 1993, 16:31-36.
4. Parfrey PS: Clinical epidemiology in chronic uraemia. Clin Invest Med 1994, 17:466-473.
5. Charra B, Laurent G, Calemard E, Terrat JC, Vanel T, Ruffet M, Chazot C: Survival on dialysis and blood pressure control. Contrib Nephrol 1994, 106:179-185. This is an extremely important study which documents that survival in patients on maintenance haemodialysis is higher if predialysis systolic blood pressure levels are in the low-normal range.
6. Ritz E, Koch M: Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 1993, 21(suppl 2):113-118.
7. Kooman JP, Leunissen KM: Cardiovascular aspects in renal disease. Curr Opin Nephrol Hypertens 1993, 2:791-797.
8. Ritz E, Deppisch R, Stier E, Hänsch G: Atherogenesis and cardiac death: are they related to dialysis procedure and blocompatibllity? Nephrol Dial Transplant 1994, 9(suppl 2):165-172.
9. European Transplantation and Dialysis Association: Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995, 10(suppl 5):12.
10. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G: Enhanced LDL oxidation in uraemic patients. An additional mechanism for accelerated atherosclerosis? Kidney Int 1994, 45:876-883.
11. Samuelsson O, Attman PO, Knight Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P: Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant 1994, 9:1580-1595.
12. US Renal Data System: Causes of death. Annual Data Report. Bethesda, Maryland: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995, 14:79-90.
13. Roig E, Betriu A, Castaner A, Magrina J, Sanz G, Navarra-Lopez F: Disabling angina pectoris with normal coronary arteries in patients undergoing haemodialysis. Am J Med 1981, 71:437-444.
14. Rostand SG, Brunzell JD, Cannon RD III, Victor RG: Cardiovascular complications in renal failure. J Am Soc Nephrol 1991, 2:1053-1062.
15. Rostand SG, Kirk KA, Rutsky EA: The epidemiology of coronary artery disease in patients on maintenance haemodialysis: Implications for management. Contrib Nephrol 1986, 52:24-41.
16. Rostand SG, Rutsky EA: Ischaemic heart disease in chronic renal failure: management considerations. Semin Dial 1989, 2:98-101.
17. Rostand SG, Kirk KA, Rutsky EA: Dialysis ischaemic heart disease: insights from coronary angiography. Kidney Int 1984, 25:653-659.
18. Parfrey PS, Hamett JD: Clinical aspects of cardiomyopathy in dialysis patients. Blood Purif 1994, 12:267-276.
19. Foley RN, Parfrey PS: Risk factors for cardiac morbidity and mortality in dialysis patients. Curr Opin Nephrol Hypertens 1994, 3:608-614.
20. Parfrey PS: Cardiac and cerebrovascular disease in chronic uraemia. Am J Kidney Dis 1993, 21:77-80.
21. Parfrey PS, Harnett JD: The management of cardiac disease in chronic uraemia. Curr Opin Nephrol Hypertens 1994, 3:145-154.
22. Parfrey PS, Harnett JD, Foley RN: Heart failure and ischaemic heart disease in chronic uraemia. Curr Opin Nephrol Hypertens 1995, 4:105-110. This review discusses lucidly the high prevalence and prognostic significance of ischaemic heart disease in dialysed patients.
23. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic cardiovascular disease in end-stage renal disease: prevalence, associations and prognosis. Kidney Int 1995, 47:186-192. This recent paper documents the impact of various patterns of LVH on clinical course and survival of dialysis patients.
24. Harnett JD, Kent KM, Barre PE, Taylor R, Parfrey PS: Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994, 4:1486-1490.
25. Harnett JD, Kent GM, Foley RN, Parfrey PS: Cardiac function and haematocrit level. Am J Kidney Dis 1995, 25(suppl 1):S3-S7.
26. Rambausek M, Ritz E, Mall G, Mehls O, Katus H: Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 1985, 28:775-787.
27. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989, 36:286-290.
28. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
29. Kaplinsky E: Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther 1994, 8(suppl 3):549-556.
30. Foley RN, Parfrey PS, Hefferton D, Singh I, Simms A, Barrett BJ: Advance prediction of early death in patients starting maintenance dialysis. Am J Kidney Dis 1994, 23:836-845.
31. Hüting J, Kramer W, Schütterle G, Wizemann V: Analysis of left ventricular changes associated with chronic haemodialysis. Nephron 1988, 49:284-290.
32. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Vissoli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991, 6:31-37.
33. Silberberg JS, Rahal DP, Patton DR, Sniderman AD: Role of anaemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 1989, 64:222-224.
34. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM: Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990, 37:137-142.
35. London GM, Pannier B, Marchais Benetos B, Safar M: Increased systolic pressure in chronic uraemia. Role of arterial wave reflection. Hypertension 1992, 20:10-19.
36. Morita S, Asou T, Kuboyama I, Tokunaga K, Harasawa Y, Sunagawa K: Increased characteristic impedance causes left ventricular hypertrophy in dogs. Circulation 1989, 80(suppl 11):299.
37. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992, 42:46-55.
38. Cannella G, Paoletti E, Delfino E, Pelosos G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialysed uraemic patients on long-term antihypertensive therapy. Kidney Int 1993, 44:881-886.
39. Suzuki H, Schaefer L, Ling H, Schaefer RM, Dämmrich J, Teschner M, Heidland A: Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE-inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol 1995, 15:129-136.
40. Devereux RB: Left ventricular geometry, pathophysiology and prognosis [Editorial Comment]. J Am Coll Cardiol 1995, 25:885-887.
41. Ruffmann K, Mandelbaum, Bommer J, Schmidly M, Ritz E: Doppler echocardiographic findings in dialysis patients. Nephrol Dial Transplant 1990, 5:426-431.
42. Fujimoto S, Kagoshima T, Hashimoto T, Nakajima T, Dohi K: Left ventricular diastolic function in patients on maintenance haemodialysis: comparison with hypertensive heart disease and hypertrophic cardiomyopathy. Clin Nephrol 1994, 42:109-116.
43. Ritz E, Ruffmann K, Rambausek M, Mall G, Schmidli M: Dialysis hypotension: is it related to diastolic left ventricular malfunction? Nephrol Dial Transplant 1987, 2:293-297.
44. Sobue T, Yokota M, Iwase M, Ishihara H: Influence of left ventricular hypertrophy on left ventricular function during dynamic exercise in the presence or absence of coronary artery disease. J Am Coll Cardiol 1995, 25:91-98.
45. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP: Risk of ventricular arrhythmias in left ventricular hypertrophy. The Framingham Heart Study. Am J Cardiol 1987, 60:560-565.
46. Post WS, Levy D: New developments in the epidemiology of left ventricular hypertrophy. Curr Opin Cardiol 1994, 9:534-541.
47. London GM, Guerin AP, Marchais SJ: Pathophysiology of left ventricular hypertrophy in dialysis patients. Blood Purif 1994, 12:277-283.
48. Wizemann V, Blank S, Kramer W: Diastolic dysfunction of the left ventricle in dialysis patients. Contrib Nephrol 1994, 106:106-109.
49. Winterton SJ, Turner MA, O'Gorman DJ, Flores NA, Sheridan DJ: Hypertrophy causes delayed conduction in human and guinea pig myocardium: accentuation during ischaemic perfusion. Cardiovasc Res 1994, 28:47-54.
50. Rössle: On the serious inflammation of the organs [in German]. Virchows Arch 1943, 311:252-284.
51. Langendorf R, Pirani CL: The heart in uraemia. Am Heart J 1947, 33:282-307.
52. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E: Myocardial interstitial fibrosis in experimental uraemia. Implications for cardiac compliance. Kidney Int 1988, 33:804-811.
53. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990, 5:39-44.
54. Amann K, Wiest G, Klaus G, Ritz E, Mall G: The role of parathyroid hormone in the genesis of interstitial cell activation in uraemia. J Am Soc Nephrol 1994, 4:1814-1819. This experimental study documents that cardiac fibrosis of uraemic animals is aborted in the absence of parathyroid hormone.
55. Weber KT, Sun Y, Tyagi SC, Cleutjens JP: Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994, 26:279-292. This extensive study details the structural changes of the cardiac interstitium associated with LVH.
56. Delano BG, Nacht R, Friedman EA, Krasnow N: Myocardial anaerobiosis in anaemia in uraemic man. Am J Cardiol 1972, 29:39-46.
57. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G: Reduced capillary density in the myocardium of uraemic rats. A stereological study. Kidney Int 1992, 42:1111-1117.
58. Törnig J, Amann K, Nichols C, Schwarz U, Zeier M, Mall G, Ritz E: Differential effects of antihypertensive treatment on abnormal cardiac structure in uraemia [Abstract]. J Am Soc Nephrol 1994, 5:796.
59. Opherk D, Mall G, Zebe H, Schwarz F, Weihe E, Manthey J, Kübler W: Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation 1984, 69:1-7.
60. Schwarzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE: Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993, 88:993-1003.
61. Amann K, Wiest G, Neusüβ R, Irzyniec T, Ritz E, Mall G: Vascular hypertrophy in uraemia is independent of hypertension. Am J Hypertens 1995, 8:409-417. This experimental study documents that, despite antihypertensive treatment, uraemic rats developed increased medial thickness pointing to non-mechanical factors in its genesis.
62. Amann K, Törnig J, Flechtenmacher C, Nabokov A, Mall G, Ritz E: Blood pressure independent wall thickening of intramyocardial arterioles in experimental renal failure - evidence for a permissive action of PTH. Nephrol Dial Transplant 1995, 10:2043-2048.